NASDAQ:ACAD ACADIA Pharmaceuticals (ACAD) Stock Price, News & Analysis $21.26 +0.16 (+0.76%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About ACADIA Pharmaceuticals Stock (NASDAQ:ACAD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ACADIA Pharmaceuticals alerts:Sign Up Key Stats Today's Range$20.91▼$21.2750-Day Range$20.32▼$22.6752-Week Range$19.69▼$28.35Volume964,966 shsAverage Volume1.72 million shsMarket Capitalization$3.64 billionP/E Ratio9.66Dividend YieldN/APrice Target$31.63Consensus RatingModerate Buy Company Overview ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics. The company’s flagship product, NUPLAZID® (pimavanserin), received U.S. Food and Drug Administration approval for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. Beyond NUPLAZID, ACADIA is pursuing additional indications for pimavanserin in dementia-related psychosis and Alzheimer’s disease psychosis, as well as exploring novel candidates for schizophrenia and other neuropsychiatric disorders. These efforts are complemented by strategic collaborations, translational research initiatives, and robust clinical trial programs to expand the company’s impact on patient care. ACADIA serves patients and healthcare providers primarily in North America, with ongoing clinical studies and regulatory submissions extending into Europe and Asia-Pacific regions. The company leverages partnerships with academic institutions and industry collaborators to accelerate development timelines and enhance its global footprint. Guided by a leadership team with extensive experience in CNS drug development, ACADIA continues to build on its scientific heritage and commitment to delivering differentiated therapies for complex neurological conditions.AI Generated. May Contain Errors. Read More ACADIA Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks82nd Percentile Overall ScoreACAD MarketRank™: ACADIA Pharmaceuticals scored higher than 82% of companies evaluated by MarketBeat, and ranked 113th out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingACADIA Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 11 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialACADIA Pharmaceuticals has a consensus price target of $31.63, representing about 48.8% upside from its current price of $21.26.Amount of Analyst CoverageACADIA Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about ACADIA Pharmaceuticals' stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth105.13% Earnings GrowthEarnings for ACADIA Pharmaceuticals are expected to grow by 105.13% in the coming year, from $0.39 to $0.80 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ACADIA Pharmaceuticals is 9.66, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.84.Price to Earnings Ratio vs. SectorThe P/E ratio of ACADIA Pharmaceuticals is 9.66, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.07.Price to Earnings Growth RatioACADIA Pharmaceuticals has a PEG Ratio of 25.54. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioACADIA Pharmaceuticals has a P/B Ratio of 2.92. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about ACADIA Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.83% of the float of ACADIA Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverACADIA Pharmaceuticals has a short interest ratio ("days to cover") of 5.89.Change versus previous monthShort interest in ACADIA Pharmaceuticals has recently increased by 1.59%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldACADIA Pharmaceuticals does not currently pay a dividend.Dividend GrowthACADIA Pharmaceuticals does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 9 people have searched for ACAD on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added ACADIA Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ACADIA Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $188,426.00 in company stock.Percentage Held by Insiders26.20% of the stock of ACADIA Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.71% of the stock of ACADIA Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ACADIA Pharmaceuticals' insider trading history. Receive ACAD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACAD Stock News HeadlinesACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Consensus Rating of "Moderate Buy" from AnalystsMay 17, 2026 | americanbankingnews.comBiopharmas look to China, elsewhere for partnerships, R&DMay 15, 2026 | msn.comThe chokepoint supplier behind SpaceX's $1.75 trillion empireWhen Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession. The world's largest supercomputer requires power equipment that takes 120 weeks to build, and Musk built Colossus in just 122 days. One small American company is positioned to close that gap faster than anyone else, yet Wall Street still prices it like an afterthought. Dylan Jovine has the full story and the ticker.May 26 at 1:00 AM | Behind the Markets (Ad)Neuren Rides DAYBUE Growth as 2025 Royalties Climb and 2026 Outlook StrengthensMay 15, 2026 | theglobeandmail.comShareholders In ACADIA Pharmaceuticals (NASDAQ:ACAD) Should Look Beyond Earnings For The Full StoryMay 14, 2026 | finance.yahoo.comACADIA Pharmaceuticals Inc. (ACAD) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 12, 2026 | seekingalpha.comEarnings Miss: ACADIA Pharmaceuticals Inc. Missed EPS By 58% And Analysts Are Revising Their ForecastsMay 11, 2026 | finance.yahoo.comJames Kihara Sells 1,332 Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) StockMay 6, 2026 | insidertrades.comSee More Headlines ACAD Stock Analysis - Frequently Asked Questions How have ACAD shares performed this year? ACADIA Pharmaceuticals' stock was trading at $26.71 at the beginning of the year. Since then, ACAD stock has decreased by 20.4% and is now trading at $21.26. How were ACADIA Pharmaceuticals' earnings last quarter? ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced its quarterly earnings results on Wednesday, May, 6th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts' consensus estimates of $0.04 by $0.02. The firm's revenue for the quarter was up 9.7% on a year-over-year basis. Read the conference call transcript. Who are ACADIA Pharmaceuticals' major shareholders? ACADIA Pharmaceuticals' top institutional investors include First Trust Advisors LP (1.95%), Dimensional Fund Advisors LP (1.84%), Pictet Asset Management Holding SA (1.19%) and Renaissance Technologies LLC (1.01%). Insiders that own company stock include Stephen Davis, Mark C Schneyer, Brendan Teehan, Austin D Kim, James Kihara, Elizabeth A Garofalo, Laura Brege, Jennifer J Rhodes and James M Daly. View institutional ownership trends. How do I buy shares of ACADIA Pharmaceuticals? Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ACADIA Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that ACADIA Pharmaceuticals investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings5/06/2026Today5/26/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 ACAD's financial health is in the Yellow zone, according to TradeSmith. ACAD has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ACAD CIK1070494 Webwww.acadia-pharm.com Phone(858) 558-2871Fax858-558-2872Employees510Year Founded1993Price Target and Rating Average Price Target for ACADIA Pharmaceuticals$31.63 High Price Target$40.00 Low Price Target$17.00 Potential Upside/Downside+48.8%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage16 Analysts Profitability EPS (Trailing Twelve Months)$2.20 Trailing P/E Ratio9.66 Forward P/E Ratio54.51 P/E Growth25.54Net Income$391 million Net Margins34.30% Pretax Margin10.51% Return on Equity9.61% Return on Assets7.07% Debt Debt-to-Equity RatioN/A Current Ratio3.59 Quick Ratio3.48 Sales & Book Value Annual Sales$1.10 billion Price / Sales3.32 Cash Flow$0.89 per share Price / Cash Flow23.78 Book Value$7.29 per share Price / Book2.92Miscellaneous Outstanding Shares171,236,000Free Float126,372,000Market Cap$3.64 billion OptionableOptionable Beta0.86 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:ACAD) was last updated on 5/26/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredElon Confirms SpaceX IPO For 6/12 [Act Now!]Elon Musk has confirmed SpaceX will IPO on Friday, June 12, 2026, at a valuation of up to $2 trillion - potent...Paradigm Press | SponsoredI was right about SpaceX. Now here's the part that mattersGoldman Sachs and JP Morgan have already been tied to allocations surrounding the SpaceX deal. When the bigges...The Oxford Club | SponsoredJune 4: The day smart money moves (not June 12)Everyone is watching June 12 - the SpaceX listing date. The real deadline is June 4, when Goldman Sachs, Morga...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ACADIA Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACAD Stock Alerts